VISEN PHARMA-B(02561),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02561 VISEN PHARMA-B

Trading 03-05 15:56:17

32.320

+0.320

+1.00%

High33.500	Low31.020	Vol1.60K
Open32.000	D1 Closing32.000	Amplitude7.75%
Mkt Cap3.68B	Tradable Cap3.68B	Total Shares114.00M
T/O50.38K	T/O Rate0.00%	Tradable Shares114.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"VISEN PHARMA-B","latestPrice":32.32,"timestamp":1772696984637,"preClose":32,"halted":0,"volume":1600,"delay":0,"changeRate":0.010000000000000009,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"Trading","change":0.32,"latestTime":"03-05 15:56:17","open":32,"high":33.5,"low":31.02,"amount":50380,"amplitude":0.0775,"askPrice":32.34,"askSize":1700,"bidPrice":31.02,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.087,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772698200000},"marketStatusCode":2,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":32,"openAndCloseTimeList":[[1772674200000,1772683200000],[1772686800000,1772697600000]],"volumeRatio":0.145993,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02561","defaultTab":"news","newsList":[{"id":"1193873570","title":"VISEN PHARMA-B (02561) Reports No Changes in Share Capital for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1193873570","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193873570?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:48","pubTimestamp":1772617693,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) released a monthly return for the period ending 28 February 2026, confirming that its authorized share capital stood at 500.00 million ordinary shares, each with a par value of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"1199340365","title":"VISEN Pharmaceuticals (2561) Schedules Board Meeting for 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1199340365","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199340365?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:37","pubTimestamp":1772444237,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (2561) announced that its board of directors will hold a meeting on 12 March 2026. Key topics include reviewing and approving the financial results for the year ended 31...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"2616112382","title":"Visen Pharmaceuticals Schedules Board Meeting to Approve Annual Results for Year Ended Dec. 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2616112382","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616112382?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:14","pubTimestamp":1772442861,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals  said its board will meet on Thursday, 12 March 2026 to consider and approve the group’s annual results for the year ended 31 December 2025 and their publication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL30JyQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"1109419182","title":"VISEN Pharmaceuticals (02561) Reports January 2026 Monthly Return on Equity Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1109419182","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109419182?lang=en_us&edition=fundamental","pubTime":"2026-02-03 17:12","pubTimestamp":1770109967,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (02561) published a monthly return on equity movements for the period ended 31 January 2026. The authorised share capital remained unchanged at 500,000,000 ordinary shares, each...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"1155302875","title":"LongPei Growth Hormone Approved, Delivering a Boost to VISEN PHARMA-B (02561) Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=1155302875","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155302875?lang=en_us&edition=fundamental","pubTime":"2026-01-27 08:55","pubTimestamp":1769475317,"startTime":"0","endTime":"0","summary":"In recent years, the trend of \"long-acting replacement\" in the domestic growth hormone market has entered an accelerated phase: the market share of long-acting growth hormones has consistently...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2606242161","title":"BRIEF-Visen Pharmaceuticals Says NMPA Approves Lonapegsomatropin (Skytrofa) For Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2606242161","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606242161?lang=en_us&edition=fundamental","pubTime":"2026-01-27 00:58","pubTimestamp":1769446698,"startTime":"0","endTime":"0","summary":"BRIEF-Visen Pharmaceuticals Says NMPA Approves Lonapegsomatropin (Skytrofa) For InjectionJan 26 (Reuters) - Visen Pharmaceuticals 2561.HK:NMPA APPROVES LONAPEGSOMATROPIN (SKYTROFA) FOR INJECTIONFurther company coverage: 2561.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YP01P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2606214350","title":"VISEN Pharmaceuticals' Growth Hormone Replacement Therapy Approved in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2606214350","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606214350?lang=en_us&edition=fundamental","pubTime":"2026-01-26 19:10","pubTimestamp":1769425820,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals  said Chinese regulators approved the company's biologics license application for lonapegsomatropin, according to a Hong Kong bourse filing Monday.The medicine, which holds the Skytrofa trade name, is meant to be used as a once-weekly growth hormone replacement therapy in patients three years and older.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2606190572","title":"Visen Pharmaceuticals - Nmpa Approves Lonapegsomatropin (Skytrofa) for Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2606190572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606190572?lang=en_us&edition=fundamental","pubTime":"2026-01-26 18:40","pubTimestamp":1769424047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YP01P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2605284018","title":"VISEN Pharmaceuticals' (HKG:2561) largest shareholders are public companies who were rewarded as market cap surged HK$412m last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2605284018","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605284018?lang=en_us&edition=fundamental","pubTime":"2026-01-24 07:45","pubTimestamp":1769211908,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over VISEN Pharmaceuticals by public companies implies that the general public has...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2561/visen-pharmaceuticals-shares/news/visen-pharmaceuticals-hkg2561-largest-shareholders-are-publi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2561/visen-pharmaceuticals-shares/news/visen-pharmaceuticals-hkg2561-largest-shareholders-are-publi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"1191373163","title":"VISEN PHARMA-B (02561) Surges Over 9% Intraday, Core Product Lonapegsomatropin Expected to Gain Approval Soon","url":"https://stock-news.laohu8.com/highlight/detail?id=1191373163","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191373163?lang=en_us&edition=fundamental","pubTime":"2026-01-23 11:58","pubTimestamp":1769140696,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) saw its shares jump more than 9% during the trading session. As of the time of writing, the stock was up 7.13%, trading at HK$37.24. According to the Insight database, the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02800","02561","BK1610"],"gpt_icon":1},{"id":"1117026279","title":"VISEN Pharmaceuticals (02561) Publishes Monthly Return for November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1117026279","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117026279?lang=en_us&edition=fundamental","pubTime":"2025-12-04 16:50","pubTimestamp":1764838216,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (Stock Code: 02561) published its monthly return for the period ended 30 November 2025. The filing shows an authorized share capital of 500,000,000 ordinary shares at par value...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"1189074067","title":"HK Stock Movement | VISEN PHARMA-B (02561) Surges Over 12% Again as Lonapegsomatropin Nears Approval; Company Recently Enters Strategic Partnership with Tofflon","url":"https://stock-news.laohu8.com/highlight/detail?id=1189074067","media":"Stock News","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189074067?lang=en_us&edition=fundamental","pubTime":"2025-12-02 11:10","pubTimestamp":1764645014,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) surged over 12% again, rising 7.11% to HKD 35.26 by the time of writing, with a turnover of HKD 1.9082 million. On the news front, Anke Biotechnology recently disclosed...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300171","BK1161","BK0251","02561"],"gpt_icon":0},{"id":"1194247422","title":"HK Stock Movement | VISEN PHARMA-B (02561) Surges Over 7% Intraday as Core Product Lonapegsomatropin Nears Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1194247422","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194247422?lang=en_us&edition=fundamental","pubTime":"2025-12-01 09:54","pubTimestamp":1764554054,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) rose more than 7% intraday, and as of press time, it was up 3.64% to HK$31.88. The catalyst behind the rally is recent progress disclosed by Anke Biotechnology regarding its...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2586288667","title":"Here's Why We're Not At All Concerned With VISEN Pharmaceuticals' (HKG:2561) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2586288667","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586288667?lang=en_us&edition=fundamental","pubTime":"2025-11-26 06:09","pubTimestamp":1764108548,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2561/visen-pharmaceuticals-shares/news/heres-why-were-not-at-all-concerned-with-visen-pharmaceutica","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2561/visen-pharmaceuticals-shares/news/heres-why-were-not-at-all-concerned-with-visen-pharmaceutica","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"1117424956","title":"Riding the Hong Kong Stock Rally: Bull Market Dawns in the East 2026 – 10th Zhitong Finance Capital Markets Annual Conference Invites You to a Capital Feast","url":"https://stock-news.laohu8.com/highlight/detail?id=1117424956","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117424956?lang=en_us&edition=fundamental","pubTime":"2025-11-18 08:56","pubTimestamp":1763427395,"startTime":"0","endTime":"0","summary":"As the fourth technological revolution sweeps across the globe, with AI and large model technologies reaching critical breakthroughs, capital engines are driving the revaluation of Chinese assets at...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06608","BK1595","06633","BK1110","BK1579","00290","BK1596","SG9999001069.SGD","LU0417516902.SGD","09996","BK1539","IE00BGHQDM52.EUR","06682","BK1131","LU1808992512.USD","BK1521","01762","00196","02420","BK1556","02105","SG9999003461.SGD","BK1139","BK1186","BK1606","09878","LU2778985437.USD","BK1230","IE00BVYPNQ40.USD","01969","02177","BK1229","HK0000252160.HKD","BK1530","BK1618","BK1516","BK1577","00699","02561","BK1163","BK1137","02488","BK1583","06100","02670","BK1141","06677","02380","BK1114","BK1542","02587","BK1188","06609","03315","01164","SG9999015978.USD","LU1634259391.SGD","01167","BK1147","BK1582","00302","LU2488822045.USD","BK1506","BK1216","LU0348825331.USD","BK1619","00867","LU2476274720.SGD","BK1161","02268","03145","02627","02533","BK1175","01907","09860","00604","LU1497733631.SGD","LU1497734951.SGD","SG9999004220.SGD","BK1221","BK1529","SG9999015945.SGD","BK1613","02096","BK1209","02157","BK1140","BK1219","09959","IE00BYV24P56.USD","BK1609","02858","BK1224","BK1524","01651","09678","02411","06090","02453","BK1124","BK1575","BK1202","BK1574","BK1593","02567","02279","01773","01333","BK1144","LU1522347837.USD","BK1183","BK1095","SG9999002950.SGD","02511","BK1142","LU0348766576.USD","02167","00552","BK1194","SG9999015986.USD","00861","BK1258","BK1527","LU1634259557.SGD","02256","00363","BK1585","BK1225","01681","BK1591","02551","IE00B543WZ88.USD","IE00BVYPNP33.GBP","00305","BK1125","BK1578","BK1207","IE00BPRC5H50.USD","01228","BK1552","02171","00826","01809","BK1228","LU0348767384.USD","LU2476274308.USD","02509","02616","BK1104","BK1116","BK1531","SG9999014674.SGD","BK1155","BK1586","BK1191","LU1497733557.USD","IE00BMCWC346.EUR","BK1109","BK1171","BK1193","01783","BK1555","02431","BK1100","BK1150","HK0000252152.HKD","02142","BK1608","03738","03658","IE00B5MMRT66.SGD","09911","BK1148","BK1132","BK1178","00382","06919","BK1500","00003","HK0000500386.USD","BK1592","BK1587","BK1518","BK1594","06069","LU2460026573.USD","01318","SG9999015952.SGD","00855","06660","06996","02886","09919"],"gpt_icon":0},{"id":"1101244851","title":"VISEN PHARMA-B (02561) Rises Over 4% as Palopegteriparatide Completes First Prescription in Boao","url":"https://stock-news.laohu8.com/highlight/detail?id=1101244851","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101244851?lang=en_us&edition=fundamental","pubTime":"2025-11-03 10:28","pubTimestamp":1762136899,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) surged over 4%, reaching HK$39.8 by the time of writing, marking a 4.68% increase. The uptick follows the recent first prescription of Palopegteriparatide (TransCon PTH) at...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2575060164","title":"VISEN Pharmaceuticals Names CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575060164","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575060164?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:35","pubTimestamp":1760358918,"startTime":"0","endTime":"0","summary":"VISEN Pharmaceuticals (HKG:2561) named Lu Ying as its CFO effective Monday, a same-day Hong Kong bourse filing said.Lu served as the CFO of VivaVision Biotech from August 2021 to October 2025.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"1174517174","title":"VISEN PHARMA-B (02561): Lu Ying Appointed as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=1174517174","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174517174?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:58","pubTimestamp":1760349507,"startTime":"0","endTime":"0","summary":"VISEN PHARMA-B (02561) announced that Lu Ying has been appointed as the company's Chief Financial Officer, effective October 13, 2025.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2575647419","title":"Visen Pharmaceuticals Appoints Lu Ying as New Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575647419","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575647419?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:58","pubTimestamp":1760349498,"startTime":"0","endTime":"0","summary":"Visen Pharmaceuticals has announced the appointment of Mr. Lu Ying as Chief Financial Officer, effective October 13, 2025. Mr. Lu brings over 19 years of financial management experience, having previously served as CFO at VivaVision Biotech Limited and held financial leadership roles at Allergan and Bayer Healthcare. The board of directors' composition remains unchanged, with Mr. Lu An-Bang continuing as Executive Director and CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Visen Pharmaceuticals published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL2ZfTkZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2575474955","title":"BRIEF-Visen Pharmaceuticals Appoints Lu Ying As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2575474955","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575474955?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:54","pubTimestamp":1760349285,"startTime":"0","endTime":"0","summary":"BRIEF-Visen Pharmaceuticals Appoints Lu Ying As CFOOct 13 (Reuters) - Visen Pharmaceuticals 2561.HK:APPOINTS LU YING AS CFOFurther company coverage: 2561.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VT01G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02561"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":-0.0303},{"period":"1month","weight":-0.0303},{"period":"3month","weight":-0.094},{"period":"6month","weight":-0.2933},{"period":"1year","weight":-0.5349},{"period":"ytd","weight":-0.0244}],"compareEarnings":[{"period":"1week","weight":-0.0566},{"period":"1month","weight":-0.057},{"period":"3month","weight":-0.0265},{"period":"6month","weight":-0.0066},{"period":"1year","weight":0.1006},{"period":"ytd","weight":-0.0149}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.","exchange":"SEHK","name":"VISEN PHARMA-B","nameEN":"VISEN PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"VISEN PHARMA-B(02561),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest VISEN PHARMA-B(02561) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"VISEN PHARMA-B,02561,VISEN PHARMA-B股票,VISEN PHARMA-B股票老虎,VISEN PHARMA-B股票老虎国际,VISEN PHARMA-B行情,VISEN PHARMA-B股票行情,VISEN PHARMA-B股价,VISEN PHARMA-B股市,VISEN PHARMA-B股票价格,VISEN PHARMA-B股票交易,VISEN PHARMA-B股票购买,VISEN PHARMA-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"VISEN PHARMA-B(02561),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest VISEN PHARMA-B(02561) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}